Finanzen von NovaBay Pharmaceuticals Inc (NBY)NBYNovaBay Pharmaceuticals Inc

NovaBay Pharmaceuticals Inc (NBY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Avenova, accounting for 88.5% of total sales, equivalent to $2.12M. Other significant revenue streams include Other products and Other revenue, net. Understanding this composition is critical for investors evaluating how NBY navigates market cycles within the Pharmaceuticals industry.

In the context of the broader market, NBY competes directly with industry leaders such as EDSA and MGX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, NBY's gross margin of N/A stands against EDSA's N/A and MGX's 100.00%. Such benchmarking helps identify whether NovaBay Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

In Q4 2025, revenue remained stagnant at 0, net income increased to -26,596,000 (up 2094.39% YoY but still negative), EPS dropped to -1.34 (down 24.72% YoY), and gross margin fell to 0 (down 100% YoY).